The board of directors of Hansoh Pharmaceutical Group Company Limited announce that, HS-10542 capsules, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria (PNH), and immunoglobulin A nephropathy (IgAN).